Researchers at Yale Cancer Center have discovered a novel metabolic gatekeeper mechanism for leukemia.
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified how breast cancer cells hide from immune cells to stay alive. The discovery could lead to better immunotherapy treatment for patients.
For patients with cancers that do not respond to immunotherapy drugs, adjusting the composition of the gut microbiome through the use of stool, or fecal, transplants may help some of these individuals respond to the immunotherapy drugs.
A targeted RNA nanoparticle designed to carry a chemotherapy drug along with a therapeutic oligonucleotide against chemical efflux gene might provide an effective treatment for liver cancer, according to a study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Keytruda (pembrolizumab) in combination with Yervoy (ipilimumab) did not improve overall survival or progression-free survival, and instead added toxicity compared with Keytruda as monotherapy in the phase III KEYNOTE-598 study.
COVID-19 continues to ramp on and has affected just about all aspects of the health care system in our country.
Jeremy Rich was named deputy director of research at UPMC Hillman Cancer Center.
Yen-Michael Hsu was named director of the Immunologic Monitoring and Cellular Therapeutics Laboratory at the UPMC Hillman Cancer Center.
Jeffrey Bradley was named interim chairman of the Emory University Department of Radiation Oncology.
The 2021 ASCO Annual Meeting will be an online only experience, June 4-8, 2021.
